Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Human gene therapy promises to change the practice of medicine by treating the causes of disease rather than the symptoms. Since the first clinical trial made its debut ten years ago, there are over 400 approved protocols in the United States alone, most of which have failed to show convincing data of clinical efficacy. This setback is largely due to the lack of efficient and adequate gene transfer vehicles. With the recent progress in elucidating the molecular mechanisms of human diseases and the imminent arrival of the post genomic era, there are increasing numbers of therapeutic genes or targets that are available for gene therapy. Therefore, the urgency and need for efficacious gene therapies are greater than ever. Clearly, the current fundamental obstacle is to develop delivery vectors that exhibit high efficacy and specificity of gene transfer. Recombinant adenoviruses have provided a versatile system for gene expression studies and therapeutic applications. Of late, there has been a remarkable increase in adenoviral vector-based clinical trials. Recent endeavors in the development of recombinant adenoviral vectors have focused on modification of virus tropism, accommodation of larger genes, increase in stability and control of transgene expression, and down-modulation of host immune responses. These modifications and continued improvements in adenoviral vectors will provide a great opportunity for human gene therapy to live up to its enormous potential in the second decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793 · cited 1×
“, 1996 ; Graham et al .”
Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725 · cited 1×
“More interes - tingly , by employing a helper virus that provided other essential functional and structural genes in trans , the generation of so - called " gutless " adenoviral vector has been recently accomplished ( Parks et al .”
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684 · cited 1×
“It has been reported that about 55% of adult humans have a low titer of neutralizing antibodies against adenovirus ( Chirmule et al .”
Viral Vectors for Gene Therapy
Robbins, P. D., & Ghivizzani, S. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00020-5 · Cited by 529
Packaging capacity and stability of human adenovirus type 5 vectors
Bett, A. J., Prevec, L., & Graham, F. L. (1993) · Journal of Virology · doi:10.1128/jvi.67.10.5911-5921.1993 · Cited by 472
Inhibition of Experimental Liver Cirrhosis in Mice by Telomerase Gene Delivery
Rudolph, K. L., Chang, S., Millard, M., Schreiber-Agus, N., & DePinho, R. A. (2000) · Science · doi:10.1126/science.287.5456.1253 · Cited by 424
Cited by
Current status of polymeric gene delivery systems☆
PARK, T., JEONG, J., & KIM, S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.03.007 · Cited by 944
A protocol for rapid generation of recombinant adenoviruses using the AdEasy system
Luo, J., Deng, Z.-L., Luo, X., Tang, N., Song, W.-X., Chen, J., Sharff, K. A., Luu, H. H., Haydon, R. C., Kinzler, K. W., et al. (2007) · Nature Protocols · doi:10.1038/nprot.2007.135 · Cited by 854
Self-citationAn overview of current delivery systems in cancer gene therapy
El-Aneed, A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.09.013 · Cited by 693
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
“In addition to adenovirus (AdV), lentivirus (LV), herpes simplex virus (HSV), adeno-associated virus (AAV), and baculovirus have also been studied for use in gene therapies.(1,3) Within the non-viral subclass, techniques utilizing naked DNA injection, electroporation, gene gun, sonoporation, magnetofection, and lipopl…”
BackgroundSelf-citationKang, Q., Sun, M. H., Cheng, H., Peng, Y., Montag, A. G., Deyrup, A. T., Jiang, W., Luu, H. H., Luo, J., Szatkowski, J. P., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302298 · Cited by 575
Self-citation
Metadata
- Authors
- Breyer, B., Jiang, W., Cheng, H., Zhou, L., Paul, R., Feng, T., & He, T.-C.
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2001-07-01
- Volume
- 1
- Issue
- 2
- Pages
- 149-162
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W2109268620
- Cited by
- 145
- References
- 6
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy. https://app.cochat.ai/papers/10.2174/1566523013348689
- The paper
- Breyer, B., Jiang, W., Cheng, H., Zhou, L., Paul, R., Feng, T., & He, T.-C. (2001). Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy. Current Gene Therapy. https://doi.org/10.2174/1566523013348689
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.